This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies
March 11-14, 2024 | Part of BPI West
Town and Country ResortSan Diego, CA

Kevin Brady, PhD
Vice President Preclinical at Cytoseek Ltd.


Kevin joined Cytoseek in November 2021, bringing with him 17 years of leadership and early phase drug discovery and development experience. He has worked in both biotech and pharma companies, and has developed new modalities and led preclinical strategies from early discovery through to end of first in human studies. He has embarked upon cross-industry regulatory responses and position papers in the field of biologics drug development. With Cytoseek he is developing the R&D strategy of our novel precision membrane engineering technology to enhance cell therapies for cancer.

Agenda Sessions

  • Artificial Membrane Binding Proteins: Precision Membrane Engineering of Cell Therapy for Cancer